NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, News & Analysis

$112.68
+1.83 (+1.65 %)
(As of 08/19/2019 04:00 PM ET)
Today's Range
$111.70
Now: $112.68
$114.15
50-Day Range
$108.37
MA: $118.22
$133.46
52-Week Range
$92.56
Now: $112.68
$141.86
Volume2.02 million shs
Average Volume1.61 million shs
Market Capitalization$25.27 billion
P/E Ratio15.89
Dividend YieldN/A
Beta1.65
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 billion
Cash Flow$9.3433 per share
Book Value$45.33 per share

Profitability

Net Income$77.60 million

Miscellaneous

Employees2,656
Market Cap$25.27 billion
Next Earnings Date10/23/2019 (Estimated)
OptionableOptionable

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.


Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings results on Wednesday, July, 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping the Zacks' consensus estimate of $2.13 by $0.51. The biopharmaceutical company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. Alexion Pharmaceuticals's revenue for the quarter was up 15.1% on a year-over-year basis. During the same period in the prior year, the company earned $2.07 EPS. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, October 23rd 2019. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of $9.65-9.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.44. The company issued revenue guidance of $4.75-4.8 billion, compared to the consensus revenue estimate of $4.78 billion.

What price target have analysts set for ALXN?

15 brokers have issued 12-month target prices for Alexion Pharmaceuticals' shares. Their forecasts range from $135.00 to $186.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $163.9333 in the next twelve months. This suggests a possible upside of 45.5% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

What is the consensus analysts' recommendation for Alexion Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

Has Alexion Pharmaceuticals been receiving favorable news coverage?

News coverage about ALXN stock has trended negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Alexion Pharmaceuticals.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Celgene (CELG), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Allergan (AGN), Amgen (AMGN), Biogen (BIIB) and Visa (V).

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 56)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
  • Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
  • Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.43%), BlackRock Inc. (7.24%), Price T Rowe Associates Inc. MD (6.28%), Jennison Associates LLC (4.02%), Nuveen Asset Management LLC (1.62%) and Invesco Ltd. (1.46%). Company insiders that own Alexion Pharmaceuticals stock include Ann M Veneman, Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which institutional investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Investec Asset Management LTD, Janus Henderson Group PLC, Janus Henderson Group PLC, AQR Capital Management LLC, Invesco Ltd., Iridian Asset Management LLC CT and Marshall Wace North America L.P.. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which institutional investors are buying Alexion Pharmaceuticals stock?

ALXN stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Renaissance Technologies LLC, Swedbank, Prudential Financial Inc., Vanguard Group Inc., BlackRock Inc., Canada Pension Plan Investment Board and Marshall Wace LLP. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $112.68.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $25.27 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.60 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,119 (Vote Outperform)
Underperform Votes:  634 (Vote Underperform)
Total Votes:  1,753
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel